Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Long path for Prolia

Wednesday, June 2nd, 2010

Amgen’s anticipated bone-strengthening drug, also known as denosumab, has notched approvals in Europe and the United States in the last five days, the latter almost two months ahead of schedule. A whirlwind week to say the least for Amgen, a company whose fate, fair or not, has been pegged largely on ...

   
©2012 UBM Canon